Evidence map›Paper›PMID 29760730›Full record

ReviewStem cells international2018

Current Progress and Challenges for Skeletal Muscle Differentiation from Human Pluripotent Stem Cells Using Transgene-Free Approaches.

Nunnapas Jiwlawat, Eileen Lynch, Jeremy Jeffrey, Jonathan M Van Dyke, Masatoshi Suzuki

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Transcriptomic Analysis across Crayfish (International journal of molecular sciences · 2024
    Article
  6. Article
  7. AFrontiers in nutrition · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. In Vitro Maturation of Human Pluripotent Stem Cell-Derived Myotubes.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nunnapas JiwlawatDepartment of Comparative Biosciences, University of Wisconsin, Madison, WI, USA.
Eileen LynchDepartment of Comparative Biosciences, University of Wisconsin, Madison, WI, USA.
Jeremy JeffreyDepartment of Comparative Biosciences, University of Wisconsin, Madison, WI, USA.ORCID 0000-0001-8271-2420
Jonathan M Van DykeDepartment of Comparative Biosciences, University of Wisconsin, Madison, WI, USA.
Masatoshi SuzukiDepartment of Comparative Biosciences, University of Wisconsin, Madison, WI, USA.ORCID 0000-0003-3253-0711
University of Wisconsin–Madison · US

Funding

Muscle stem cells: New ALS growth factor therapy and disease modelR01NS091540 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI SUZUKI, MASATOSHI · 2015 to 2019
$1.7M
NINDS NIH HHS R01 NS091540
6 · The paper itself

Abstract

Neuromuscular diseases are caused by functional defects of skeletal muscles, directly via muscle pathology or indirectly via disruption of the nervous system. Extensive studies have been performed to improve the outcomes of therapies; however, effective treatment strategies have not been fully established for any major neuromuscular disease. Human pluripotent stem cells have a great capacity to differentiate into myogenic progenitors and skeletal myocytes for use in treating and modeling neuromuscular diseases. Recent advances have allowed the creation of patient-derived stem cells, which can be used as a unique platform for comprehensive study of disease mechanisms,

Identifiers

PMID29760730
PMCPMC5924987
OpenAlexW2797081253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.